TY - JOUR
T1 - Recurrent Hodgkin lymphoma
T2 - Toward a new definition of candidates for autologous stem cell transplant in the era of positron emission tomography scan and novel agents
AU - Pinto, Antonello
AU - Corradini, Paolo
AU - Mussetti, Alberto
AU - Zinzani, Pier Luigi
PY - 2015/7/1
Y1 - 2015/7/1
N2 - Standard treatment for patients with Hodgkin lymphoma (HL) unresponsive to upfront therapy or relapsing after primary treatment (RR-HL) consists of salvage chemotherapy followed by autologous stem cell transplant (ASCT). ASCT outcomes are essentially related to two factors: disease burden at the time of transplant and comorbidity status of the patient. Positron emission tomography (PET) scan is a very sensitive diagnostic instrument to measure disease status. In fact, a negative PET status before ASCT is a well-known positive prognostic factor in patients with RR-HL. The recent introduction of the biologically targeted agent brentuximab vedotin has allowed us to treat RR-HL more efficaciously with less toxicity for the patient. Use of this new agent could help achieve a PET-negative status before ASCT in a larger percentage of patients, without severe toxicities, thereby improving ASCT outcomes. Herein we discuss the current evolving scenario of RR-HL treatment.
AB - Standard treatment for patients with Hodgkin lymphoma (HL) unresponsive to upfront therapy or relapsing after primary treatment (RR-HL) consists of salvage chemotherapy followed by autologous stem cell transplant (ASCT). ASCT outcomes are essentially related to two factors: disease burden at the time of transplant and comorbidity status of the patient. Positron emission tomography (PET) scan is a very sensitive diagnostic instrument to measure disease status. In fact, a negative PET status before ASCT is a well-known positive prognostic factor in patients with RR-HL. The recent introduction of the biologically targeted agent brentuximab vedotin has allowed us to treat RR-HL more efficaciously with less toxicity for the patient. Use of this new agent could help achieve a PET-negative status before ASCT in a larger percentage of patients, without severe toxicities, thereby improving ASCT outcomes. Herein we discuss the current evolving scenario of RR-HL treatment.
KW - Antibody-based immunotherapy
KW - Clinical results
KW - Lymphoma and Hodgkin disease
UR - http://www.scopus.com/inward/record.url?scp=84938124744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84938124744&partnerID=8YFLogxK
U2 - 10.3109/10428194.2014.981174
DO - 10.3109/10428194.2014.981174
M3 - Article
C2 - 25363402
AN - SCOPUS:84938124744
VL - 56
SP - 1969
EP - 1974
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
SN - 1042-8194
IS - 7
ER -